ARGATROBAN ACUTE MYOCARDIAL INFRACTION STUDY

本研究的主要目的是评价和比较急性MI 接受溶栓性链激酶治疗的患者， 凝血酶抑制剂阿加曲班的剂量在加速 冠状动脉血栓 终点为：死亡、复发性心肌梗死， 血管成形术，冠状动脉旁路移植术，新发充血性心脏病 衰竭和复发性缺血。 GCRC将以 运行盲态稀释剂并混合非盲态IV研究药物，监测PTT 并根据方案中的描述调整研究药物剂量。

The primary objective of this study is to evaluate and compare acute MI patients receiving the thrombolytic streptokinase and either high or low dose of the thrombin inhibitor, Argatroban in accelerating the lysis of coronary artery clots. The end points are: death, recurrent MI, angioplasty, coronary artery bypass grafting, new onset congestive heart failure and recurrent ischemia. The GCRC will act in the capacity of an Runblind investigatorS and mix unblinded IV study drug, monitor the PTT and make adjustments in study drug dose as delineated in the protocol.